London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: Bk2011, 13 Jun 2024 19:30
Last post: Bk2011, 13 Jun 2024 19:30
A 1 billion dollar plus sale looks to be on the cards for Probiotix Health biggest customer.
https://ca.news.yahoo.com/probiotics-maker-seed-health-explores-164523574.html
Started: mol42, 9 Jun 2024 19:07
Last post: mol42, 9 Jun 2024 19:07
Started: Bk2011, 23 May 2024 09:46
Last post: martinu, 6 Jun 2024 15:21
Yes, Bk thanks for posting. Let's hope it gets some mainstream media coverage. (With hopefully some ref to LPldl /PBX).
Esp as yesterday, this was in the news.
https://www.theguardian.com/society/article/2024/jun/05/bowel-disease-hope-researchers-find-biological-pathway
I agree. A pbx rns on this would have provided a boost to the flagging share price. I hope they atleast mention it in the results whenever they are announced.
Thanks for posting that BK and noting the clinically meaningful results ""A multi-species synbiotic (DS-01) alleviates irritable bowel syndrome symptoms while boosting synbiotic consortium: A randomized, double-blind, placebo-controlled clinical trial."
This clinical trial assessed the impact of DS-01® in patients with Irritable Bowel Syndrome (IBS). Key findings include:
DS-01® led to a significant and clinically meaningful improvement in abdominal pain among participants with IBS.
DS-01® led to an enrichment of synbiotic and endogenous beneficial bacteria.
DS-01® led to a significant increase in serotonin in IBS-M participants, a potential mechanism of action.
These presentations will detail the methodology and results from the two clinical trials which have important implications for the application of microbiome science in consumer health and well-being.
Seed's Health clinical data on DS-01® Daily Synbiotic for antibiotic recovery and IBS will be presented in the session "Prebiotics, Probiotics and Synbiotics in Health and Disease" on May 20, 2024, from 12:30 PM to 1:30 PM EDT."
I hat PBX at the very least did not see fit to at least issue a RNS Reach announcing this, after all Seed Health account for most of the re venue generated here so anything that can lead to a meaningful increase in DS01 sales will have a material impact on revenue surely?
Started: mol42, 4 Jun 2024 17:51
Last post: mol42, 4 Jun 2024 17:51
With only 1 week to go until Probiota Americas 2024, the leading microbiome industry event, our team is getting ready to head out to Salt Lake City, Utah, and connect with leading experts from around the world.
This year, as a proud gold sponsor at the event, the ProBiotix team will be present with a stand for you to discuss more on how we are leading the way in probiotic research and product solutions for cardiometabolic health. Samples of the new innovative InstaMelt stick formulation will also be available to try and take away.
We'll also be presenting our innovative application concepts for LPLDL®, our award-winning probiotic strain for cardiometabolic health. Don't forget to drop by and say hello to the team.
and there we are
https://probiotaamericas.com/live/en/page/partners
mol
Started: mol42, 30 Apr 2024 18:02
Last post: mol42, 28 May 2024 19:42
A bit more
https://probiotixhealth.com/free-product-trial-vitafoods/
mol
C 5hours ago from the under noted
ProBiotix Health
407 followers
5h
Did you spot us in the latest edition of Nutramedic & Cosmetics in its Vitafoods Europe 2024 preview? Our innovative InstaMelt formulation is launching at the exhibition.
Visit us at stand P56 to learn more, or discover why it's great for cardiometabolic health
yes i did - lol
it's where i got the blurb as posted
https://nmc-magazine.com/vitafoods-europe-2024-preview/
mol
Booth: P56
ProBiotix Health launches new innovative InstaMelt formulation to support cardiometabolic health.
ProBiotix Health Plc (‘ProBiotix’), a life sciences company that develops finished probiotic formulations to support cardiometabolic health, has launched InstaMelt – a newly developed food supplement that offers innovative features for health brands and retailers to rebrand as a full turn-key solution.
Featuring two science-backed and natural ingredients, the InstaMelt formulation contains the company’s proprietary ingredient LPLDL®, a patented probiotic strain with proven efficacy from multiple independent human intervention studies to significantly decrease LDL and increase HDL cholesterol levels, and Thiamine (Vitamin B1), which supports heart function.
ProBiotix has a keen interest in healthy ageing solutions that not only add years to life but add life to years. With global life expectancy rising, health spans must also rise to meet that expectation.
Niels Peter Bak, Head of Product Management at ProBiotix, commented: “Our InstaMelt formulation uses InstaMelt technology, a unique dosing technology to help health brands deliver the patented strain in a novel and convenient way. Its superior organoleptic properties, combined with natural fruit flavours, make the InstaMelt formulation a great addition to any heart health and wellness portfolio.”
Available in redberry and peach flavours, visitors will be able to taste InstaMelt at stand P56, alongside viewing the company’s full product range.
mol
Started: mol42, 28 May 2024 19:24
Last post: mol42, 28 May 2024 19:29
In fact all product info flyers updated May 2024 - see product info
https://probiotixhealth.com/products/
mol
mol
Flyer uploaded May 2024
https://probiotixhealth.com/wp-content/uploads/2024/05/YourBiotix-InstaMelt-For-Cholesterol-Health-1.pdf
mol
Started: martinu, 22 May 2024 18:02
Last post: martinu, 22 May 2024 18:02
My message (sent for attn of S Andersen) rather than addressed to Walbrook
"Dear Mr Andersen,
I know I am not alone among shareholders in thinking that communication with us, since PBX went alone, has been lacking.
I understood from Walbrook that you were going to set out plans for 2024. We are almost half way through the year, and still nothing.
In the half year figures, orders received though not all booked, had exceeded revenues for all of 2022. Please could you provide a trading update.
Finally, I would love to add to my shareholding, but am loath to do so whilst on Aquis. Please get a listing on PBX. [edit my error, but I think they know I mean AIM]
Many thanks
Martin U"
And Walbrook's response
"Thank you for your email. We had planned to do an update before now, but various external factors prevented this unfortunately. Your comments are noted and I will pass them on to Steen. We will certainly be doing an update at the results."
Started: mol42, 21 May 2024 19:02
Last post: mol42, 21 May 2024 19:02
Such a simple thing to do and file before overdue
https://find-and-update.company-information.service.gov.uk/company/11330264
anybody at home?
mol
mol
Started: AustinTexas, 12 May 2024 08:56
Last post: Bk2011, 15 May 2024 16:18
1.5m in orders in the first 6 months. We have no way to know if they were all delivered and invoiced in 2023.
They have to announce results by the end of June so not long to wait now.
This is a longer extract from H1 2023.
"During the first half of the financial year the Group received confirmed orders totalling £1.5m which is 16% greater than turnover for the period to 31 December 2022 of £1.31m. Of the orders received, £552k (2021: £302k) had been completed and invoiced as at 30 June 2023. The increase in sales for the first half of the year reflects strong development in new customer acquisition as well as growth from existing customers. Gross profit for the period amounted to £264k (2022: £154k)."
A lot depends on how much of orders are actually booked. And indeed, paid for in reasonable time.
Sales up to the end of June 2023 for H1 were 550k. I don't understand where the 750k comes from?
I looking forward to full year figures for 2023, SOH has mentioned back in April 23 that they had done sales of £750k in first 4 months of 2023 and projected sales of £2.5m for year end - being very profitable.
This stock seems to get forgotten about being on this exchange but I think people will hopefully take more notice after results.
Started: mol42, 14 May 2024 17:36
Last post: martinu, 15 May 2024 09:53
Yes, i missed this. Thanks.
C 3 weeks ago
Steen Dannemann Andersen
Chief Executive Officer & Board member
3w
Dear network
Is there ANY chance that you might know someone, dynamic, driven by “hunting” and all aspects of hands-on sales and customer interaction? Someone who has 3-5 years under the belt and is ready for his or her next professional sales challenge. If you do, please, please put me in contact with that person.
I have a sales job proposal which is hard to resist, in an exceptional organization full of ambitions, entrepreneurship, team spirit and room for shaping own workday to create a healthy work/life balance.
We are committed to support healthy living under the motto “it is not about adding years to life but adding life to years”. Our dedication has led to exceptionally fast growth of the company. Our value proposition is to offer consumers clinically documented natural probiotic supplements supporting maintenance of healthy cholesterol and blood pressure levels throughout life. Our dietary supplement products are brought to market by leading regional and global companies under their own brand.
Our mission is real as almost 20 million people die from cardiovascular diseases every year of which 4 million are directly linked to elevated cholesterol levels. If our products by any means could just fractionally support lowering that numbers our mission is accomplished.
We are expanding rapidly out of our headquarters in Denmark, and the ideal profile would be someone willing to work from HQ as basis, but as the role covers sales in all of Europe, he or she also could be based in another Scandinavian or European country.
hmm...
obviously otherwise engaged martinu to provide the update noted in your approach to Walbrook
anyway 30 June 2024 rapidly approaching re 31 Dec 2023 audited financial statements due
mol
Started: mol42, 9 May 2024 17:02
Last post: skipsharer, 10 May 2024 10:58
And rebranded to yourbiotix (albeit the old cholbiome still has a presence on clicking a number of the links and of course still on opti online as same)
https://probiotixhealth.com/
https://probiotixhealth.com/products/
mol
Started: mol42, 7 May 2024 16:39
Last post: mol42, 7 May 2024 16:39
A further US patent granted 20 February 2024
https://patents.justia.com/patent/11903979#history
albeit doesn't at moment seem to have been assigned to pbx though i'm no expert in these matters and it is not the first according to list below
https://patents.justia.com/inventor/stephen-patrick-o-hara
mol
Started: Adyan9200, 26 Apr 2024 11:41
Last post: Adyan9200, 26 Apr 2024 11:41
Has there been any update of how well the company did in 2023 and what the outlook is for 2024 as well any update on new product development etc.
The last real RNS with that type of info was on "27 Sep 2023 - Half-year Report" which covered to 30 June 2023. I'd have thought the full year report would have been released by now.
Started: AquaeSulis01, 9 Apr 2024 19:24
Last post: AquaeSulis01, 19 Apr 2024 13:22
My wife has been smoking for over 50 years and also hasn't had any side effects yet but not sure that should reassure anyone about the impact of cigarettes. The bottom line is that as LPLDL is clinically proven to lower cholesterol on its own, why persevere with a product containing red yeast at levels considered unsafe by other jurisdictions?
"Q. My bad cholesterol has been rising, and my doctor suggested that I start taking a statin. I've read that red yeast rice has many of the cholesterol-lowering benefits of a statin, and I would rather go the natural route. However, I recently heard on a newscast that red yeast rice can have adverse effects on the kidneys. Is it still safe for me to take this supplement?
A. It's true that red yeast rice, which contains monacolin K, a chemical that's identical to the active ingredient in the cholesterol-lowering drug lovastatin (Mevacor), may reduce your LDL (bad) cholesterol and lower your total cholesterol. However, an independent analysis of a dozen 600-milligram (mg) capsules of red yeast rice products conducted a few years ago found that the actual monacolin K content varied widely — from 0.1 mg to 10.9 mg. (The lowest dose of lovastatin is 20 mg.) In addition, one-third of the products were contaminated with a potentially toxic compound called citrinin, which can damage the kidneys. The Food and Drug Administration (FDA) has blocked the sale of red yeast rice supplements that contain enough of the active ingredient to make them as effective as lovastatin because they haven't undergone the drug approval process. Unlike FDA-approved drugs, supplements can be sold without proof of effectiveness and purity."
https://www.health.harvard.edu/cholesterol/can-i-use-red-yeast-rice-instead-of-a-statin-to-lower-my-cholesterol
I've been using x3 for 1 year now....great product and very effective.
no side effects or issues with it what so ever!
Typical. I bought a box of that the other day
Already banned in US and heavily restricted in the EU, issues now raised in Japan. Amazed PBX still sells Cholbiome X3 in the UK
https://www.bbc.co.uk/news/world-asia-68662585
Started: martinu, 3 Apr 2024 20:06
Last post: martinu, 3 Apr 2024 20:06
Today, I sent yet another follow up to this exchange with Walbrook from early Dec.
"Apologies for the delay. I was on holiday when you sent the original email and it fell under my radar after I got back. The Company is working constantly on delivering milestones and increasing liquidity. The latter is difficult in these markets, but they have a defined strategy in place. For your information, we intend to hold an investor presentation (hosted on the IMC platform) in the New Year where Steen will lay out the plans for 2024 and how he and the Board plan to delivery growth."
Got a prompt reply!
"We will be holding an IMC for PBX. And we will let the market know... as soon as we have a date!"
Started: DireCons, 26 Feb 2024 07:40
Last post: martinu, 26 Feb 2024 16:25
Thanks for putting me straight on this. It is the same company as referred to in half year report.
Thanks BK, translation of the page below
"Dual-Level Support: SymbioLife® Cholesterol Control* provides support to our body on two levels, naturally normalizing cholesterol levels.
It contains the bacterium Lactobacillus plantarum LPLDL®, harnessing the significant impact of natural bacteria on our health. Intestinal bacteria, particularly of the Lactobacillus genus, can regulate our cholesterol levels by binding to cholesterol or incorporating it into their own cell membranes.
The specific intestinal bacterium Lactobacillus plantarum LPLDL® also increases our excretion of bile acids. As a result, our body produces more bile acids, which are essential for fat digestion, and in turn, removes cholesterol from the blood.
In addition to this, SymbioLife® Cholesterol Control contains phytosterols*, secondary plant compounds that possess a structure similar to cholesterol. When we consume phytosterols, our intestinal wall transports them into our body instead of cholesterol.
The remaining cholesterol in the intestine is then excreted with the stool, leading to a decrease in cholesterol levels"
The rns states...
SymbioPharm has introduced the CholBiome® CH formulation as a premium pharmacy supplement solution across targeted regions...
Sounds like the formulation is already on sale?
Agree Dire, guess we have to wait for the partner to set up its manufacturing capability before an eventual launch then
Started: mol42, 20 Feb 2024 19:32
Last post: AquaeSulis01, 26 Feb 2024 09:08
Seed Health never announced the outcome of their clinical study into DS01 for treating Irritable Bowel Syndrome despite the clinical study finishing over a year ago so guess may well have been inconclusive which is a pity
No not us per se but seed in at no 4 according to Success magazine
Most Innovative Company in Health & Wellness
4. Seed Health Inc.
Who they are: Seed is a direct-to-consumer, research-backed probiotic company whose products are available for a monthly subscription fee of $49.99.
How they innovate: The company believes “the science of probiotics demands a new standard.” Currently, the company offers just two consumer products; however, the science and testing that go into their products is anything but limited. Based on robust clinical research, it collects probiotic strains and puts them to the test in a high-tech simulator known as SHIME®, which mimics biological conditions from stomach to colon. Formula information and testing data are transparent and accessible, and its scientific board includes researchers from the National Institutes of Health’s Human Microbiome Project.
Financials: Seed is a privately held company; revenue and earnings are not publicly available. According to WWD, the company raised $40 million in Series A funding in 2021.
Impact: Seed’s combination of scientific rigor, social impact work and award-winning product design, plus a subscription model that eliminates the overhead of brick-and-mortar retail, make it a standout in an otherwise overcrowded and underregulated supplements industry.
https://www.success.com/most-innovative-companies-2024/
mol
Started: mol42, 23 Aug 2023 18:32
Last post: mol42, 20 Feb 2024 16:28
Tom now moved to Business Development Manager, as he is at Optibiotix, from Feb 2024
https://uk.linkedin.com/in/tom-o-hara-6a8686184
I'll just leave it at that
mol
Albeit perhaps no one has told Tom
https://uk.linkedin.com/in/tom-o-hara-6a8686184
lol
mol
Looks like position filled
From dec 23
Global Supply Chain Director
https://dk.linkedin.com/in/mads-brandt-96849b1?trk=people-guest_people_search-card
think director is used solely in the context of the position (sounds better - at least to some - not me) rather than a director of
probiotix health plc
which still persists in using seborg as head quarters and to this date hasn't explained the apparent subsidiary involving our CEO
https://uk.linkedin.com/company/probiotix-health?trk=public_profile_experience-item_profile-section-card_subtitle-click
mol
Taking over from T O'Hara seemingly
https://uk.linkedin.com/in/tom-o-hara-6a8686184
mol
Https://alumniglobal.com/job/head-of-supply-chain-pro-biotix-health
hardly surprising advertised in Denmark considering CEO and our recent technical product manager
another deerland employee perhaps to be appointed .......
anyway we were notified of increased employment numbers during 2023 - which per se I'm not opposed to - in fact welcome in order to grow the business - just hope it is the best people being appointed
and of course we haven't been notified of anything further on our new subsidiary, which i discovered several months ago now involving our new CEO, and its seemingly business purpose having not a lot to with lpldl nor anything remotely associated with probiotics
mol
Started: aspex, 7 Feb 2024 22:26
Last post: martinu, 8 Feb 2024 12:50
I thought the £1m cost of moving to AIM was an initial figure. Thought SOH said it would be cheaper 18 months (?) after IPO. And if I've remembered correctly, I would support a move to AIM. I don't have loads of spare cash but would happily top up eg monthly at these prices.
There is little if any trading PBX on the Aquis platform.
The spread is horrendous . Up to 4p
There appears to be no access for Aquis Only shares on any international platforms.
The cost to move to AIM is quoted by SOH is up to £1m so based on 125m shares well under 1p for each share.
Liquidity is critical and Aquis does not perform or is ever likely to.
Time for the CEO to find a way out of this quagmire.
NOW!
Started: martinu, 7 Feb 2024 13:49
Last post: martinu, 7 Feb 2024 13:49
Another new position.
https://www.linkedin.com/jobs/view/sales-manager-at-probiotix-health-131090497
Started: mol42, 1 Jan 2024 17:47
Last post: martinu, 5 Feb 2024 07:37
PBX at Probiota event. From this Wed to Fri.
https://www.linkedin.com/company/probiotix-health?trk=feed_main-feed-card_feed-actor-name
RNS to confirm Michael L appt today, and departure of Mikkel HH.
He almost seems more suited to Skinbiotix.
Https://www.dksh.com/vn-en/home/media/news?id=en-2fbb8064-beb5-43dc-8522-f0849299996b:1-lt
and we know that
https://www.loreal.com/en/press-release/research-and-innovation/loreal-acquires-research-firm-lactobio/
what will become of our commercial director?
mol
Has worked at Deerland, Bifodan and most recently, Lactobio. Another "chief"? So will have to prove his worth.
Started: martinu, 22 Nov 2023 14:21
Last post: aspex, 3 Feb 2024 18:47
O’Hara should have realised a long time ago that staying on Aquis restricts the share price notably on the spread but particularly that no international brokers include PBX as tradable.
That alone stops interest. Shares that are on Aquis as extra to their AIM listing for example are
unaffected. So for anyone outside UK has only expensive full service brokers to turn to and low flexibility.
It seems to be “Fiddling while Rome burns”
What happens if Probiotix did move to AIM. Would our shares automatically get moved over to AIM?
I currently have mine in a iWeb account, but as they don't offer Aquiss exchange, I would have to move them to a provider who does. I was hoping Probiotix would move to AIM.
Chased up Walbrook this am re Steen's proposed presentation on plans for 2024. Prompt reply but no date yet. I asked them to give him a nudge. :)
Cheers martinu
increasing liquidity is difficult in these markets - lol
impossible on aquis
mol
Great, we get to hear from Steen a year after he took up the role
Started: mol42, 1 Jan 2024 18:21
Last post: mol42, 16 Jan 2024 17:23
Research that was carried out prior to trial presumably
https://www.mdpi.com/2624-5647/6/1/8
mol
Efficacy of Cholesterol-lowering L. Plantarum on Cardiometabolic Health Biomarkers in Coeliac Disease Patients
Study Purpose
Recent studies have also shown that 30% of the world’s population carries the susceptibility genes for coeliac disease and that only 2-5% of these individuals are really affected, however, studies suggest the existence of other factors capable of contributing to the onset of the disease, such as intestinal dysbiosis. We have also seen how each of us has a specific microbiota, defined as an individual human enterotype, which depends on our background and can be modified by the diet. Recently, much interest has been directed to a strain of lactobacilli, called Lactobacillus plantarum (LP-LDL®) capable of reducing cholesterol and preventing the reabsorption of bile salts in the liver. The efficacy of this bacterial strain has been confirmed in 3 different human studies demonstrating the efficacy of LP-LDL® in patients with high baseline cholesterol (TC> 6mmol / L). This is a food supplement that has been commercially available in multiple formulations in Europe for over 3 years. LP-LDP is a probiotic strain, safe to use, selected for its high bile salt hydrolase in vitro, and in vivo cholesterol reduction activity. The intake of 2 Å~ 109 CFU encapsulated LP-LDL twice daily, significantly reduced LDL-C (13.9%), total cholesterol (TC) (37.6%), TG (53.9%), and significantly increased HDL-C (14.7%; in subjects >60 years of age; 6-12 weeks) in normal to mildly hypercholesterolaemic subjects. In a recent double-blind placebo-controlled human study published by the Journal of Functional Foods (2022) and carried out by the University of Roehampton (UK), LPLDL showcased statistically significant reductions in multiple cardiovascular risk biomarkers, including total cholesterol, LDL cholesterol, non-HDL cholesterol and apoB. No adverse effects were noted throughout the study. We are here proposing a pilot human intervention study to evaluate the effectiveness of the LP-LDL® probiotic in reducing cardiovascular risk factors inclusive of cholesterol in the blood in people with coeliac disease.
Recruiting in Italy - UK still to recruit
https://clinicaltrials.gov/study/NCT06178107
also noted on
https://trials.celiac.org/trials/NCT06178107
mol
Started: mol42, 26 Dec 2023 16:37
Last post: mol42, 26 Dec 2023 16:37
Review of seed ds-01 191223
https://www.si.com/showcase/nutrition/seed-probiotic-review
mol
From 14-21 nov 23 by the looks of it
URL Images Last Mod.
https://probiotixhealth.com/ 17 2023-11-21 11:35 +00:00
https://probiotixhealth.com/corporate/ 5 2023-11-14 12:37 +00:00
https://probiotixhealth.com/contact-us/ 9 2023-11-16 13:19 +00:00
https://probiotixhealth.com/lpldl/ 15 2023-11-16 16:28 +00:00
https://probiotixhealth.com/products/ 5 2023-11-16 16:47 +00:00
https://probiotixhealth.com/scientific-studies/ 1 2023-11-17 09:44 +00:00
https://probiotixhealth.com/about-us/ 9 2023-11-21 09:59 +00:00
mol
Has had a more than welcome makeover
https://probiotixhealth.com/
I tend to check the undernoted more than the above
https://probiotixhealth-ir.com/
so hadn't noticed albeit picture is familiar from this year
mol